Health Care - As enacted, authorizes a physician to perform stem cell therapy or regenerative medicine therapy that is not approved by the United States food and drug administration if such therapy is used for a treatment or procedure that is within the scope of practice of the physician; makes related changes. - Amends TCA Title 63 and Title 68.

SB 2586 establishes new regulations for stem cell therapies in Tennessee, directly affecting physicians and facilities providing these treatments. It requires stem cells used in therapy to be retrieved, manufactured, and stored only in facilities registered with the FDA and accredited by specific organizations like the American Association of Tissue Banks. The bill mandates that physicians disclose in advertisements that the therapy is not FDA-approved and must use products meeting federal manufacturing standards. It explicitly excludes therapies using cells derived from fetuses or embryos after abortion. The law aims to ensure safety through facility accreditation, viability testing, and clear patient disclosures.